Proactive Investors - Run By Investors For Investors

Abcam given a shot in the arm by Goldman Sachs

Abcam given a shot in the arm by Goldman Sachs

Shares in Abcam (LON:ABC), which manufactures antibodies used in clinical research, were given a shot in the arm by Goldman Sachs.

Placing the Abcam on its ‘conviction buy’ list, the American investment bank said there was the potential for the stock to climb over 50% in the next six months. Its price target of 645p reflects this.

“We believe Abcam can continue to grow ahead of the broader consumable life science tools market through share gains and a shift towards more technologically advanced products, where it has a high share and which contribute a higher gross margin,” said analyst Carl Hazeley.

“The company’s proprietary data asset that grows through user-generated content should drive attachment and reliance on its products. 

“This, in turn, should support a positive pricing dynamic. We forecast significant cash generation owing to Abcam’s capitallight business model, and expect cash to be deployed towards bolt-on acquisitions and special dividends.”

The shares, off 12% in the year to date, rose 1.5% to 431p.

View full ABC profile View Profile

Abcam Timeline

January 10 2017

Related Articles

May 09 2019
Here we take a look under the hood of Shield Therapeutics
young girl with allergy
April 29 2019
The sell-off that followed the recent disappointment of Allergy’s PQ Birch jab means now might be a good time to invest, according to City broker finnCap
Medical scanner
February 08 2019
The company’s digital platform and Artificial Intelligence (AI) software manages and helps interpret images from MRI (magnetic resonance imaging) and PRT (positron emission tomography) scanners

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use